ConcR
Opportunity
Treatment resistance is responsible for 90% of cancer related deaths and consumes approximately 30% of the total cancer care spend.
Solution
ConcR exists to tackle this issue, combining cutting edge machine learning techniques and knowledge of tumour progression. The software provides clinicians with evidence-based outputs of patient-specific cancer progression, enabling therapy adaptation before treatment resistance arises.